EGFR and exanthem: Furthermore, from a clinical point of view, the only parameter which has been constantly associated with a high probability of response, prolonged progression-free survival (PFS) and median Overall Survival (mOS) to anti-EGFR moAbs treatment is the development of skin rash [2], [5], [32].